Massari, Francesco; Ciccarese, Chiara; Hes, Ondrej; Michal, Michal; Caliò, Anna; Fiorentino, Michelangelo; Giunchi, Francesca; D'Amuri, Alessandro; Sanguedolce, Francesca; Sabbatini, Roberto; Guida, Annalisa; Ardizzoni, Andrea; Porta, Camillo; Iacovelli, Roberto; Tortora, Giampaolo; Cima, Luca; Ortega, Cinzia; Lapini, Alberto; Martignoni, Guido; Brunelli, Matteo, The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome, «PATHOLOGY ONCOLOGY RESEARCH», 2018, 24, pp. 447 - 456 [Scientific article]
Massari, Francesco; Ciccarese, Chiara; Hes, Ondrej; Michal, Michal; Caliò, Anna; Fiorentino, Michelangelo; Giunchi, Francesca; D’Amuri, Alessandro; Sanguedolce, Francesca; Sabbatini, Roberto; Guida, Annalisa; Ardizzoni, Andrea; Porta, Camillo; Iacovelli, Roberto; Tortora, Giampaolo; Cima, Luca; Ortega, Cinzia; Lapini, Alberto; Martignoni, Guido; Brunelli, Matteo*, The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome, «PATHOLOGY ONCOLOGY RESEARCH», 2018, 24, pp. 447 - 456 [Scientific article]
Santoni M.; Massari F.; Piva F.; Carrozza F.; Di Nunno V.; Cimadamore A.; Martignetti A.; Montironi R.; Battelli N., Tivozanib for the treatment of renal cell carcinoma, «EXPERT OPINION ON PHARMACOTHERAPY», 2018, 19, pp. 1021 - 1025 [Scientific article]
Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E, Bortolus R, Fratino L, Gobitti C, Lamaj E, Ghedini P, Rizzini EL, Massari F, Dionisi V, Fanti S, Volterrani D, Monari F., 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience., «TUMORI», 2018, 104(2), pp. 128 - 136 [Scientific article]
Cimadamore A.; Scarpelli M.; Piva F.; Massari F.; Gasparrini S.; Doria A.; Cheng L.; Lopez-Beltran A.; Montironi R., Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets, «FUTURE ONCOLOGY», 2017, 13, pp. 1105 - 1114 [Scientific article]
Ciccarese C.; Iacovelli R.; Brunelli M.; Massari F.; Bimbatti D.; Fantinel E.; De Marco V.; Porcaro A.B.; Martignoni G.; Artibani W.; Tortora G., Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies, «EUROPEAN JOURNAL OF CANCER», 2017, 83, pp. 237 - 246 [Scientific article]
Massari F.; Di Nunno V.; Ciccarese C.; Graham J.; Porta C.; Comito F.; Cubelli M.; Iacovelli R.; Heng D.Y.C., Adjuvant therapy in renal cell carcinoma, «CANCER TREATMENT REVIEWS», 2017, 60, pp. 152 - 157 [Scientific article]
Munari E.; Cima L.; Massari F.; Bertoldo F.; Porcaro A.B.; Calio A.; Riva G.; Ciocchetta E.; Ciccarese C.; Modena A.; Iacovelli R.; Sava T.; Eccher A.; Ghimenton C.; Tortora G.; Artibani W.; Novella G.; Bogina G.; Zamboni G.; Sanguedolce F.; D'Amuri A.; Martignoni G.; Brunelli M., Cathepsin K expression in castration-resistant prostate carcinoma: A therapeutical target for patients at risk for bone metastases, «THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS», 2017, 32, pp. 243 - 247 [Scientific article]
Ciccarese, Chiara; Montironi, Rodolfo; Fiorentino, Michelangelo; Martignoni, Guido; Brunelli, Matteo; Iacovelli, Roberto; Lopez-Beltran, Antonio; Cheng, Liang; Scarpelli, Marina; Moch, Holger; Tortora, Giampaolo; Massari, Francesco, Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?, «CURRENT DRUG METABOLISM», 2017, 18, pp. 0 - 0 [Scientific article]
Iacovelli, Roberto*; Cossu Rocca, Maria; Galli, Luca; De Giorgi, Ugo; Sabbatini, Roberto; Santoni, Matteo; Mosca, Alessandra; Fornarini, Giuseppe; Massari, Francesco; Masini, Cristina; Bersanelli, Melissa; Biasco, Elisa; Lolli, Cristian; Guida, Annalisa; Berardi, Rossana; Terrone, Carlo; Pastorino, Alessandro; Ardizzoni, Andrea; Pinto, Carmine; Buti, Sebastiano; Nolè, Franco; Tortora, Giampaolo, Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer, «UROLOGIC ONCOLOGY», 2017, 35, pp. 541 - 541.e13 [Scientific article]
Cimadamore A.; Gasparrini S.; Scarpelli M.; Doria A.; Mazzucchelli R.; Massari F.; Cheng L.; Lopez-Beltran A.; Montironi R., Epigenetic modifications and modulators in prostate cancer, «CRITICAL REVIEWS IN ONCOGENESIS», 2017, 22, pp. 439 - 450 [Scientific article]
Ciccarese C.; Di Nunno V.; Iacovelli R.; Massari F., Future perspectives for personalized immunotherapy in renal cell carcinoma, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2017, 17, pp. 1049 - 1052 [Scientific article]
Bianconi M.; Faloppi L.; Lopez-Beltran A.; Cheng L.; Cimadamore A.; Gasparrini S.; Massari F.; Scarpelli M.; Montironi R., Immunotherapy in genitourinary cancers: Where are we going?, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2017, 2, pp. 73 - 78 [Scientific article]
Ciccarese C.; Montironi R.; Iacovelli R.; Massari F., Localized prostate cancer genotyping: Another step towards personalized therapy, «TRANSLATIONAL CANCER RESEARCH», 2017, 6, pp. 246 - 248 [Scientific article]Open Access
Conteduca V.; Caffo O.; Lolli C.; Aieta M.; Scarpi E.; Bianchi E.; Maines F.; Schepisi G.; Salvi S.; Massari F.; Carrozza F.; Veccia A.; Chiuri V.E.; Campadelli E.; Facchini G.; De Giorgi U., Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone, «THE PROSTATE», 2017, 77, pp. 1012 - 1019 [Scientific article]
